Nuedexta is already FDA-approved for pseudobulbar affect in ALS patients, but this study aims to provide evidence for its efficacy in improving bulbar functions such as speech and swallowing. The potential for expanded indications could enhance market positioning against competitors targeting ALS symptom management. Given the increasing prevalence of ALS and the limited treatment options available, successful outcomes may lead to significant commercial opportunities. Companies should conduct thorough diligence on the competitive landscape, particularly focusing on emerging therapies that address bulbar dysfunction.